Apposite Capital

Kelso Pharma is an innovative pharmaceutical manufacturing company focused on improving patient outcomes through the development and distribution of branded medications. By prioritizing cost-effectiveness, Kelso Pharma aims to meet the diverse needs of patients, helping them recover from various illnesses. The firm is dedicated to enhancing the healthcare market by providing high-quality medications designed to benefit patients and support their health and well-being.

Mirada Medical Limited is a developer of medical imaging software applications, enhancing patient outcomes in radiology, molecular imaging, radiation oncology, and multidisciplinary meetings across hospitals, imaging centers, and cancer centers. The company offers several key products, including Mirada XD, an enterprise software for nuclear medicine and image fusion; DLCExpert, which provides automated organ-at-risk contouring services; and Mirada IM, supporting interventional medicine, particularly in optimizing radioembolization therapy. Established in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, Mirada Medical sells its solutions through direct sales and distribution channels, focusing on integrating advanced technology with practical applications for the diagnosis and treatment of cancer and other diseases.

CrestOptics is a company specializing in the development and manufacture of advanced systems for fluorescence microscopy. Based in Rome, Italy, the firm leverages its proximity to renowned research institutions to foster collaboration on innovative projects, including partnerships with organizations like CNR – FISBAT. CrestOptics focuses on creating high-performance microscopy instruments that utilize optical and electrooptical technology, enhancing sensitivity, image quality, and clarity for both scientific and industrial applications. The company also benefits from the expertise of its partner, Crisel Instruments, which has over 15 years of experience in live cell imaging systems. Through its commitment to research and development, CrestOptics aims to provide state-of-the-art solutions tailored to the needs of the research community and various industrial sectors.

i2a SA is a diagnostic and medical informatics company based in Montpellier, France, specializing in microbiology. Established in 1988 by three engineers from Polytechnique, the company manufactures and markets instruments, software, and reagents tailored for microbiology laboratories and infection prevention services, primarily in Europe and North America. i2a's product lineup includes the Sirscan2000, an automatic reader for disc diffusion susceptibility tests, and various software solutions designed for monitoring susceptibility tests and epidemiological data. The company also provides essential reagents for bacteriology, such as rapid susceptibility test media and antibiotic discs. i2a is particularly notable for its strong presence in France, where it supplies around 75% of hospitals, and aims to expand its international reach in the coming years. By consistently adapting its products to meet user needs, i2a enhances its development potential and innovation within the field of microbiology.

1Med is a contract research organization (CRO) that provides a comprehensive range of clinical research services tailored to meet the needs of clinical trials. The company specializes in regulatory strategy, clinical trial management, and quality assurance, supporting businesses throughout the entire product lifecycle. This includes services from initial design and development to certification, covering regulatory, medical, preclinical, and clinical aspects. By offering these integrated solutions, 1Med enables organizations to maintain essential internal competencies and effectively achieve their objectives in the complex landscape of clinical research.

Emblation specializes in medical microwave technology, focusing on the development and commercialization of innovative solutions for the oncology, dermatology, and podiatry sectors. The company designs and manufactures microwave-based products aimed at treating various skin conditions and associated health issues. Their technology is centered on the precise destruction of tissue and the immune activation effects of microwave treatments, enhancing the capabilities of healthcare professionals in delivering effective patient care. Emblation’s offerings support advancements in medical research and product development, contributing to improved treatment protocols in their targeted fields.

Archway Dental Practice Limited, established in 1996 and located in Dursley, United Kingdom, offers a range of dental services primarily to private patients in the Dursley and Stroud areas. With over 15 years of experience, the practice provides high-quality dental care, including surgical procedures, diagnostics, and screening services. As of September 3, 2019, Archway Dental Practice operates as a subsidiary of Riverdale Healthcare Limited.

Mirada Medical Limited is a developer of medical imaging software applications, enhancing patient outcomes in radiology, molecular imaging, radiation oncology, and multidisciplinary meetings across hospitals, imaging centers, and cancer centers. The company offers several key products, including Mirada XD, an enterprise software for nuclear medicine and image fusion; DLCExpert, which provides automated organ-at-risk contouring services; and Mirada IM, supporting interventional medicine, particularly in optimizing radioembolization therapy. Established in 1999 and headquartered in Oxford, United Kingdom, with an additional office in Denver, Colorado, Mirada Medical sells its solutions through direct sales and distribution channels, focusing on integrating advanced technology with practical applications for the diagnosis and treatment of cancer and other diseases.

Riverdale Healthcare is a new dentistry investment group to provide high quality, ethical dentistry.

Prime Health Diagnostics Ltd is a healthcare facility based in Weybridge, United Kingdom, that specializes in diagnostic, treatment, and fitness services. The company provides a wide array of medical and diagnostic offerings, including consultant clinics, private general practitioner services, advanced 3T MRI scans, ultrasound, and X-ray imaging. Additionally, Prime Health offers therapeutic and fitness services such as physiotherapy, osteopathy, personal training, Pilates, nutritional therapy, podiatry, sports massage, and performance coaching. Established in 2010, the facility aims to deliver comprehensive healthcare and fitness solutions to clients, enabling them to optimize their overall health and well-being.

OrthoD is a specialist manufacturer and distributor of medical products and implants for joint reconstruction, sport medicine, surgical products and infection control applications.

Swanton Care & Community specializes in providing residential and supported living services for adults with complex learning disabilities, mental health disorders, and acquired brain injuries. The company operates 24 care homes across East Anglia, the West Midlands, South West Wales, the North East, and Scotland, offering a total of 259 registered beds. In addition to residential care, Swanton has a growing supported living service in key localities. The organization employs approximately 780 staff members and generated revenues of £25 million in the most recent fiscal year. Swanton emphasizes collaboration with patients' families, healthcare professionals, and care teams to understand individual needs, focusing on enablement and promoting independence, allowing patients to take an active role in setting their own goals and outcomes.

NIMGenetics is a diagnostic center authorized by the Madrid Health Authority, specializing in high-resolution genomic systems for precise clinical diagnosis. The company employs advanced genomic and next-generation sequencing (NGS) microarray technologies to analyze genetic information, which aids in the diagnosis of various clinical disorders. Its focus spans multiple medical disciplines, including gynecology, neurology, pediatrics, and oncology. By providing reliable and accurate genetic diagnoses, NIMGenetics supports medical professionals in enhancing patient health outcomes for those affected by genetic diseases. The organization's scientifically accredited team is dedicated to advancing the field of medical genetics through innovative diagnostic solutions.

Enara Group specializes in delivering high-quality home care services in the UK, catering to individuals who need assistance due to illness, disability, or infirmity. The company offers a diverse range of care options, ensuring tailored support for its clients. Enara works with various funding sources, including local authorities, the National Health Service (NHS), and private pay agreements, allowing it to reach a broad demographic and provide essential services to those in need.

Complete Care is a healthcare service provider specializing in high acuity care for individuals with complex clinical needs across England and Wales. The company supports approximately 150 clients, offering rehabilitative care and assistance for conditions such as cerebral palsy, motor neuron diseases, and muscular dystrophy. With a workforce of around 650 personal care assistants, including registered nurses, Complete Care focuses on delivering personalized healthcare within the comfort of patients' homes, facilitating their recovery and improving their overall health. This approach not only enhances patient well-being but also complements existing domiciliary care operations in the region.

MiHomecare offers a comprehensive range of homecare services designed to assist individuals who require support due to age, illness, disability, or other health challenges. The company focuses on enabling clients to maintain their independence within their own homes. Its services include personal care, medication assistance, meal preparation, and light housekeeping. Additionally, MiHomecare provides live-in care, ensuring clients receive personalized attention and companionship. The company also specializes in complex care services, catering to those with more intricate health needs.

Medical Imaging Partnership is a provider of radiology services established by UK Radiologists to deliver high-quality imaging services to both private and NHS patients. The organization aims to ensure fast access to expert-led services for patients and referrers alike. Its offerings include a range of fully managed clinical services such as MRI, CT, ultrasound, X-ray, dual-energy X-ray absorptiometry scans, and ultrasound-guided steroid injections. Medical Imaging Partnership is recognized for its commitment to excellence, providing reports from leading specialist Radiologists. Additionally, it is accredited by major private medical insurers and offers competitive self-pay pricing, making reliable health tests and checkups accessible to a broad audience.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Cancer Partners UK is a provider of cancer treatment services that operates a network of purpose-built cancer centres throughout the United Kingdom. Each centre is uniquely designed to cater to the specific needs of its local community and offers a variety of services, including diagnostics, chemotherapy, radiotherapy, and palliative care. The organization emphasizes patient-focused care, ensuring that from the initial referral by a general practitioner, patients have prompt access to necessary diagnostic procedures and comprehensive treatment options, all available in one location. By maintaining high standards across its centres, Cancer Partners UK aims to deliver consistent, high-quality care to individuals facing cancer.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.

Ulthera is a medical technology company based in Mesa, Arizona, specializing in ultrasound-based devices for aesthetic procedures. The company focuses on noninvasive techniques for skin rejuvenation, aiming to deliver safe and effective results in the growing market for energy-based therapies. The Ulthera® System utilizes patented DeepSEE™ technology, which combines imaging and therapeutic capabilities of ultrasound to meet the needs of the aesthetic industry. Originally conceived for image-guided cancer therapy, Ulthera has evolved over several years to address the demand for advanced elective medical procedures.

Convergence Pharmaceuticals is an independent biotechnology company established in October 2010 after acquiring specific neuroscience clinical assets from GlaxoSmithKline. The company specializes in the development of innovative analgesics, focusing on small molecule sodium channel blockers designed to address neuropathic pain. Its pipeline includes differentiated clinical-stage compounds that target key points in chronic pain signaling through the modulation of specific ion channels, aiming to achieve favorable efficacy, responder rates, and side effect profiles.

SureCalm Healthcare is dedicated to delivering high-quality homecare services for patients managing long-term chronic conditions. The company specializes in providing stoma care and continence devices, along with home delivery and personalized care services. Additionally, SureCalm has recently launched an internet and mail order pharmacy, which offers clients a comprehensive range of medication and related advice. By focusing on these essential services, SureCalm Healthcare aims to support patients in their daily health management within the comfort of their own homes.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions. The company offers innovative treatments for diseases such as rheumatoid arthritis, metabolic disorders, fibrosis, and nonalcoholic steatohepatitis. Utilizing a proprietary technology platform, Bird Rock Bio focuses on developing monoclonal antibodies that target G-protein coupled receptors (GPCRs), which are critical for therapeutic specificity. Among its key products is RYI-008, a highly selective antibody targeting IL-6, a cytokine involved in inflammation and cancer. Bird Rock Bio aims to meet the medical needs of patients in China while also seeking to create global market opportunities. The company, originally known as RuiYi Inc., was established in 2006 and is headquartered in La Jolla, California, with a research facility in Shanghai, China.

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.

PharmaKodex is a pharmaceutical company that develops and commercializes small molecule drugs for treating pain and neurological conditions. The company was founded in 2006 and is based in Cambridge, the United Kingdom with an additional office in Chippenham, the United Kingdom. As of February 23, 2009, PharmaKodex Ltd. operates as a subsidiary of Orexo AB.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.